Last reviewed 2026-05-14 · How we verify

Fluad and Prevenar13

This is a combination of two vaccines: Fluad (inactivated influenza vaccine) and Prevenar13 (pneumococcal conjugate vaccine) that stimulate immune responses against influenza and pneumococcal pathogens.

This is a combination of two vaccines: Fluad (inactivated influenza vaccine) and Prevenar13 (pneumococcal conjugate vaccine) that stimulate immune responses against influenza and pneumococcal pathogens. Used for Prevention of seasonal influenza, Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae.

At a glance

Mechanism of action

Fluad is an inactivated influenza vaccine that contains viral antigens to induce antibody production against seasonal influenza strains. Prevenar13 is a 13-valent pneumococcal conjugate vaccine that conjugates pneumococcal polysaccharide antigens to a protein carrier to enhance immune response against 13 serotypes of Streptococcus pneumoniae. Together, they provide protection against both influenza and invasive pneumococcal disease.

Approved indications

• Prevention of seasonal influenza
• Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae

Common side effects

• Injection site pain, erythema, or swelling
• Fever
• Myalgia
• Fatigue

Key clinical trials

• Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Fluad and Prevenar13 CI brief — competitive landscape report
• Fluad and Prevenar13 updates RSS · CI watch RSS
• Korea University Guro Hospital portfolio CI